{"denoms":[{"counts":[{"groupId":"BG000","value":"955"},{"groupId":"BG001","value":"960"},{"groupId":"BG002","value":"952"},{"groupId":"BG003","value":"2867"}],"units":"Participants"}],"groups":[{"description":"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m\\^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m\\^2 infusion over 2 hours, followed by 5-fluorouracil (5-FU), given as a 400 mg/m\\^2 bolus injection, and then as a 600 mg/m\\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\\^2 (alone), followed by 5-FU 400 mg/m\\^2 bolus injection, and 5-FU 600 mg/m\\^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).\n\nWeeks 25-48: Observation only.","id":"BG000","title":"FOLFOX4"},{"description":"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m\\^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m\\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\\^2 bolus injection, and then as a 600 mg/m\\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\\^2 (alone), followed by 5-FU 400 mg/m\\^2 bolus injection, and 5-FU 600 mg/m\\^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).\n\nWeeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).","id":"BG001","title":"FOLFOX4 + Bv"},{"description":"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m\\^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m\\^2 twice daily (equivalent to a total daily dose of 2000 mg/m\\^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).\n\nWeeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).","id":"BG002","title":"XELOX+Bv"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"68"},{"groupId":"BG003","value":"219"}]}],"title":"<40"},{"categories":[{"measurements":[{"groupId":"BG000","value":"603"},{"groupId":"BG001","value":"625"},{"groupId":"BG002","value":"588"},{"groupId":"BG003","value":"1816"}]}],"title":"40-65"},{"categories":[{"measurements":[{"groupId":"BG000","value":"275"},{"groupId":"BG001","value":"261"},{"groupId":"BG002","value":"296"},{"groupId":"BG003","value":"832"}]}],"title":">=65"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"425"},{"groupId":"BG001","value":"473"},{"groupId":"BG002","value":"432"},{"groupId":"BG003","value":"1330"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"530"},{"groupId":"BG001","value":"487"},{"groupId":"BG002","value":"520"},{"groupId":"BG003","value":"1537"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"123"},{"groupId":"BG003","value":"377"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"33"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"791"},{"groupId":"BG001","value":"813"},{"groupId":"BG002","value":"795"},{"groupId":"BG003","value":"2399"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"56"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"}],"populationDescription":"Baseline Measures are based on the Intent-to-Treat - Stage III Disease Patient Population."}